Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Topkan, Erkan ^a   Parlak, Cem ^a   Topuk, Savas ^a   Pehlivan, Berrin ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b Memorial Health Group   (Turkey)

Author keywords

Concurrent chemotherapy; Glutamine supplementation; Lung cancer; Radiotherapy; Survival outcome; Tumor growth

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; GLUTAMINE; METOCLOPRAMIDE; NAVELBINE;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRESCRIPTION; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; WEIGHT CHANGE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESOPHAGITIS; FEMALE; FOLLOW-UP STUDIES; GLUTAMINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84868224703     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-502     Document Type: Article

References (51)

1. Chapet O, Fraas BA, Ten Haken RK. Multiple fields may offer better esophagus sparing without increased probability of lung toxicity in optimized IMRT of lung tumors. Int J Radiat Oncol Biol Phys 2006, 65:255-265. 10.1016/j.ijrobp.2005.12.028, 16618580.
2. Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, Mitchell JB. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 2010, 15(4):360-71. 10.1634/theoncologist.2009-S104, 3076305,3076305, 20413641.
3. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003, 29(6):501-513. 10.1016/S0305-7372(03)00133-6, 14585260.
4. Kuhn KS, Muscaritoli M, Wischmeyer P, Stehle P. Glutamine as indispensable nutrient in oncology: experimental and clinical evidence. Eur J Nutr 2010, 49(4):197-210. 10.1007/s00394-009-0082-2, 19936817.
5. Kapadia C, Muhlbacher F, Smith R. Alterations in glutamine metabolism in response to operative stress and food deprivation. Surg Forum 1982, 33:19-21.
6. Rouse K, Nwokedi E, Woodliff JE, Epstein J, Klimberg VS. Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann Surg 1995, 221(4):420-426. 10.1097/00000658-199504000-00014, 1234593, 7726679.
7. Klimberg VS, Nwokedi B. LF H: Does glutamine facilitate chemotherapy while reducing its toxicity?. Surg Forum 1991, 42:16-18.
8. Carretero J, Obrador E, Pellicer JA, Pascual A, Estrela JM. Mitochondrial glutathione depletion by glutamine in growing tumor cells. Free Radic Biol Med 2000, 29(9):913-923. 10.1016/S0891-5849(00)00392-0, 11063916.
9. Algara M, Rodriguez N, Vinals P, Lacruz M, Foro P, Reig A, Quera J, Lozano J, Fernandez-Velilla E, Membrive I, et al. Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. Int J Radiat Oncol Biol Phys 2007, 69(2):342-349. 10.1016/j.ijrobp.2007.03.041, 17531398.
10. Topkan E, Yavuz MN, Onal C, Yavuz AA. Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters. Lung Cancer 2009, 63(3):393-399. 10.1016/j.lungcan.2008.06.015, 18691789.
11. Bourhis J, Blanchard P, Maillard E, Brizel DM, Movsas B, Buentzel J, Langendijk JA, Komaki R, Swan Leong S, Levendag P, et al. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. J Clin Oncol 2011, 29(18):2590-2597. 10.1200/JCO.2010.33.1454, 21576630.
12. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009, 373(9674):1532-1542. 10.1016/S0140-6736(09)60502-X, 19410717.
13. Eagle H. Nutritional needs of mammalian cells in tissue culture. Science 1935, 122:501.
14. Collins CL, Wasa M, Souba WW, Abcouwer SF. Determinants of glutamine dependence and utilization by normal and tumor-derived breast cell lines. J Cell Physiol 1998, 176:166-178. 10.1002/(SICI)1097-4652(199807)176:1<166::AID-JCP18>3.0.CO;2-5, 9618156.
15. Sauer LA, Dauchy RT. Ketone body, glucose, lactic acid, and amino acid utilization by tumors in vivo in fasted rats. Cancer Res 1983, 43:3497-3503.
16. Choi K, Lee SS, Oh SJ, Lim SY, Lim SY, Jeon WK, Oh TY, Kim JW. The effect of oral glutamine on 5-fluorouracil/ leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr 2007, 26:57-62. 10.1016/j.clnu.2006.07.003, 16949180.
17. Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chiou TJ, Liu JH, Yen CC, Chen PM. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007, 12:312-319. 10.1634/theoncologist.12-3-312, 17405895.
18. Monteforte MJ, Turkelson CM. Bariatric surgery for morbid obesity. Obes Surg 2000, 10(5):391-401. 10.1381/096089200321594246, 11054242.
19. Cox JD, Stez J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31:1341-1346. 10.1016/0360-3016(95)00060-C, 7713792.
20. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35(13):1773-1782. 10.1016/S0959-8049(99)00229-4, 10673991.
21. Bartlett DL, Charland S, Torosian MH. Effect of glutamine on tumor and host growth. Ann Surg Oncol 1995, 2(1):71-76. 10.1007/BF02303705, 7530589.
22. Klimberg VS, Souba WW, Salloum RM, Plumley DA, Cohen FS, Dolson DJ, Bland KI, Copeland EM. Glutamine-enriched diets support muscle glutamine metabolism without stimulating tumor growth. J Surg Res 1990, 48(4):319-323. 10.1016/0022-4804(90)90066-B, 2338817.
23. van der Hulst RR, van Kreel BK, von Meyenfeldt MF, Brummer RJ, Arends JW, Deutz NE, Soeters PB. Glutamine and the preservation of gut integrity. Lancet 1993, 341(8857):1363-1365. 10.1016/0140-6736(93)90939-E, 8098788.
24. Shewchuk LD, Baracos VE, Field CJ. Dietary L-glutamine supplementation reduces the growth of the Morris Hepatoma 7777 in exercise-trained and sedentary rats. J Nutr 1997, 127(1):158-166.
25. Klimberg VS, Souba WW, Dolson DJ, Salloum RM, Hautamaki RD, Plumley DA, Mendenhall WM, Bova FJ, Khan SR, Hackett RL, et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 1990, 66(1):62-68. 10.1002/1097-0142(19900701)66:1<62::AID-CNCR2820660113>3.0.CO;2-E, 2354410.
26. Klimberg V. How glutamine protects the gut during irradiation. J Crit Care Nutr 1996, 3:21-25.
27. Jensen JC, Schaefer R, Nwokedi E, Bevans DW, Baker ML, Pappas AA, Westbrook KC, Klimberg VS. Prevention of chronic radiation enteropathy by dietary glutamine. Ann Surg Oncol 1994, 1(2):157-163. 10.1007/BF02303560, 7834441.
28. Souba WW, Klimberg VS, Hautamaki RD, Mendenhall WH, Bova FC, Howard RJ, Bland KI, Copeland EM. Oral glutamine reduces bacterial translocation following abdominal radiation. J Surg Res 1990, 48(1):1-5. 10.1016/0022-4804(90)90136-P, 2296175.
29. Salman B, Oguz M, Akmansu M, Bebitoglu I, Akca G, Sultan N, Emre U, Kerem M, Yilmaz U. Effect of timing of glutamine-enriched enteral nutrition on intestinal damage caused by irradiation. Adv Ther 2007, 24(3):648-661. 10.1007/BF02848790, 17660176.
30. Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM, Yeh SA, Hsu HC, Hsiung CY. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 2000, 46(3):535-539. 10.1016/S0360-3016(99)00402-2, 10701731.
31. Yoshida S, Matsui M, Shirouzu Y, Fujita H, Yamana H, Shirouzu K. Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer. Ann Surg 1998, 227(4):485-491. 10.1097/00000658-199804000-00006, 1191301, 9563534.
32. Cerchietti LC, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, Cabalar ME, Roth B, Negretti G, Sheinker B, et al. Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006, 65(5):1330-1337. 10.1016/j.ijrobp.2006.03.042, 16765532.
33. Anderson PM, Ramsay NK, Shu XO, Rydholm N, Rogosheske J, Nicklow R, Weisdorf DJ, Skubitz KM. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 1998, 22(4):339-344. 10.1038/sj.bmt.1701317, 9722068.
34. Schloerb PR, Skikne BS. Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. JPEN J Parenter Enteral Nutr 1999, 23(3):117-122. 10.1177/0148607199023003117, 10338217.
35. Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001, 7(5):1192-1197.
36. Li Y, Yu Z, Liu F, Tan L, Wu B, Li J. Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: a prospective randomized trial. Tumori 2006, 92(5):396-401.
37. Bode BP, Kaminski DL, Souba WW, Li AP. Glutamine transport in isolated human hepatocytes and transformed liver cells. Hepatology 1995, 21(2):511-520.
38. Fischer CP, Bode BP. WW S: Adaptive alterations in cellular metabolism with malignant transformation. Ann Surg 1998, 227(2):627-634. 1191335, 9605654.
39. Knox WE, Horowitz ML, Friedell GH. The proportionality of glutaminase content to growth rate and morphology of rat neoplasms. Cancer Res 1969, 29(3):669-680.
40. Obrador E, Carretero J, Esteve JM, Pellicer JA, Pascual A, Petschen I, Estrela JM. Glutamine potentiates TNF-alpha-induced tumor cytotoxicity. Free Radic Biol Med 2001, 31(5):642-650. 10.1016/S0891-5849(01)00622-0, 11522449.
41. Fahr MJ, Kornbluth J, Blossom S, Schaeffer R, Klimberg VS, Harry M. Vars Research Award. Glutamine enhances immunoregulation of tumor growth. JPEN J Parenter Enteral Nutr 1994, 18(6):471-476. 10.1177/0148607194018006471, 7602720.
42. El-Malt M, Ceelen W, Boterberg T, Claeys G, de Hemptinne B, de Neve W, Pattyn P. Does the addition of glutamine to total parenteral nutrition have beneficial effect on the healing of colon anastomosis and bacterial translocation after preoperative radiotherapy?. Am J Clin Oncol 2003, 26(3):e54-59.
43. Kozelsky TF, Meyers GE, Sloan JA, Shanahan TG, Dick SJ, Moore RL, Engeler GP, Frank AR, McKone TK, Urias RE, et al. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol 2003, 21(9):1669-1674. 10.1200/JCO.2003.05.060, 12721240.
44. Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010, 28(23):3739-3745. 10.1200/JCO.2009.24.5050, 20625120.
45. Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010, 28(20):3299-3306. 10.1200/JCO.2009.24.7577, 20530281.
46. Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011, 29(17):2312-2318. 10.1200/JCO.2010.31.7875, 3107747, 21555682.
47. Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103(19):1452-1460. 10.1093/jnci/djr325, 3186782, 21903745.
48. Brade A, Bezjak A, MacRae R, Laurie S, Sun A, Cho J, Leighl N, Pearson S, Southwood B, Wang L, et al. Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011, 79(5):1395-1401. 10.1016/j.ijrobp.2010.01.014, 20605367.
49. Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, Garst J, Brotherton T, Vokes EE. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 2011, 29(23):3120-3125. 10.1200/JCO.2010.33.4979, 3157978, 21747084.
50. El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 2003, 89(12):2184-2189. 10.1038/sj.bjc.6601418, 2395273, 14676792.
51. Koukourakis M, Hlouverakis G, Kosma L, Skarlatos J, Damilakis J, Giatromanolaki A, Yannakakis D. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 1996, 34(2):315-322. 10.1016/0360-3016(95)02102-7, 8567332.